Lung Cancer

Lung cancer is the world's most common cancer and kills more people than any other cancer. In 2008, approximately 1.52 million new cases of lung cancer were diagnosed worldwide, with 1.31 million people dying from the disease.(14) In the United States, an estimated 161,840 deaths, accounting for 29 percent of all cancer deaths, occurred in 2008, according to the American Cancer Society (ACS).

Lung Cancer

Lung cancer is a common and very serious form of cancer, with more than 40,000 people diagnosed with the condition each year in the UK. The symptoms of lung cancer do not present in the early stages, but when symptoms do eventually present, they usually include the following:

Lung Cancer in Women: Understanding the Increasing Risk

Lung Cancer Diagnosis

Lung Cancer Treatments

Epidemiology of Lung Cancer

Palliative and End-of-Life Care in Lung Cancer

Lung Cancer Research

Everything You Need to Know About Giving Up Cigarettes

Lung Cancer Symptoms

Lymph Nodes in Lung Cancer

Carcinogens in Cigarette Smoke

Lung Cancer Pathogenesis

See more featured articles »

What are the Survival Rates for Lung Cancer?

Lung Cancer and Electrolyte Imbalances

Pulmonary Resection in Lung Cancer

What Causes Lung Cancer in Non-Smokers?

Lung Cancer Risk Factors

Lung Cancer Questions

Lung Cancer Genetics

Pulmonary Transplant (Lung Transplant)

Immunotherapy: The Future of Lung Cancer Treatment?

Lung Plethysmography Procedure

How to Prevent Lung Cancer

Lung Cancer Causes

Lung Cancer Screening Procedure

Exploring Diversity in Lung Cancer: Impact on Incidence, Prognosis, and Treatment Strategies

Types of Lung Cancer Surgery

Secondary Lung Cancer

Lung Cancer: Radiotherapy and Chemotherapy

Latest Lung Cancer News and Research

AI model predicts immunotherapy-related pneumonitis risk from CT scans

Researchers at The University of Texas MD Anderson Cancer Center have developed an artificial intelligence (AI) model that can identify lung cancer patients at increased risk of developing a serious immunotherapy-related side effect before treatment begins, offering a possible path toward more personalized monitoring and prevention strategies.

24 Sep 2026

Breath test shows promise for identifying cancerous lung nodules

The human breath could help identify cancerous lung nodules negating the need for invasive testing.

23 Sep 2026

Cancer incidence rises faster among people with type 2 diabetes

A nationwide study being presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) has found that people with type 2 diabetes (T2D) have a higher risk of developing cancer, with cancer incidence rising more among people with T2D than those without diabetes over the past 25 years, largely driven by obesity-related cancers.

22 Sep 2026

Simple prompts may improve cancer screening compliance among high-risk groups

People getting recommended screening tests for one cancer can be reminded about other relevant screenings. It's a simple way to increase compliance for potentially life-saving tests.

22 Sep 2026

Low spinal bone density may predict faster brain aging

Researchers at Johns Hopkins University found that lower bone mineral density in the spine was associated with faster cognitive decline and accelerated age-related white matter injury, according to a new study published today in Radiology, a journal of the Radiological Society of North America.

22 Sep 2026

New international standard creates unified health data across Europe

Every breath we take contains tiny particles that are invisible to the naked eye and can harm our health. Air pollution alone contributes to heart disease, stroke, lung cancer, and other chronic illnesses.

21 Sep 2026

Y chromosome loss creates hidden cancer vulnerability in men

A study initiated by a University of Arizona Cancer Center physician-scientist Dr. Dan Theodorescu revealed that the loss of the Y chromosome in men's body tissue could pave the way for cancer to develop in that tissue.

18 Sep 2026

Wildfire smoke may be more harmful than other air pollution, two Mount Sinai studies find

As climate change drives more frequent and intense wildfires, researchers at the Icahn School of Medicine at Mount Sinai have published two large-scale studies showing that wildfire smoke may pose greater health risks than other sources of air pollution, with higher risks of hospitalization for cardiovascular and respiratory disease and poorer survival among patients with lung cancer.

18 Sep 2026

Diaceutics launches Precision for All Strategic Collaboration at Fierce Pharma Week 2026

Intelligence and engagement company, Diaceutics, is bringing together senior voices from across the biopharmaceutical industry at the Precision for All Strategic Collaboration, launching at Fierce Pharma Week 2026.

From Diaceutics PLC 18 Sep 2026

Study identifies powerful inherited risk factor for lung cancer

A rare inherited mutation in the Epidermal Growth Factor Receptor (EGFR) gene is associated with a 25-fold increased risk of lung cancer, according to a study by investigators at Dana-Farber Cancer Institute and 23andMe Research Institute.

17 Sep 2026

Wildfire smoke poses greater health risks than other pollution

17 Sep 2026

Existing anti-seizure drug slows the growth of diffuse midline gliomas

An existing anti-seizure drug slows the growth of a devastating group of childhood cancers, new Stanford Medicine-led research has shown.

17 Sep 2026

AI tools help predict immunotherapy outcomes in lung cancer patients

Artificial intelligence (AI) tools can help physicians predict treatment and survival outcomes in patients with advanced non-small cell lung cancer (NSCLC) treated with immunotherapy, according to a new study published in Nature Medicine.

16 Sep 2026

Lung Facts updated with latest evidence on respiratory disease across 21 countries

The International Respiratory Coalition (IRC) has updated its Lung Facts platform with the latest evidence on the burden of respiratory disease across 21 countries, providing policymakers, clinicians and patient advocates with updated data to drive national-level policy action on lung health.

16 Sep 2026

Genomic profiling uncovers distinct TP53 and PI3K pathways across tumor budding grades

A newly proposed International Association for the Study of Lung Cancer (IASLC) tumor budding-based grading system successfully identified patients with resected lung squamous cell carcinoma (SqCC) at higher risk of poor outcomes and showed potential to help guide selection for adjuvant chemotherapy, according to research presented at the IASLC 2026 World Conference on Lung Cancer on Lung Cancer. (WCLC).

15 Sep 2026

Stage 1 findings support continued pivotal phase evaluation of gotistobart

Patients with metastatic squamous non-small cell lung cancer (NSCLC) whose disease progressed following PD-(L)1 inhibitor therapy experienced a median overall survival of 18.5 months with the investigational anti-CTLA-4 antibody gotistobart compared with 10.0 months for patients receiving docetaxel, according to updated findings from Stage 1 of the Phase 3 PRESERVE-003 trial.

15 Sep 2026

Mobile LDCT lung cancer screening can reach vulnerable populations in resource-limited settings

Mobile low-dose computed tomography (LDCT) screening can reach high-risk and socially vulnerable populations in resource-limited settings, according to initial results from the Third Brazilian Early Lung Cancer Trial (BRELT3) presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

15 Sep 2026

Research identifies novel prognostic biomarkers for class II and III BRAF-altered cancers

Patients with metastatic non-small cell lung cancer (NSCLC) harboring class II and class III BRAF alterations have distinct clinicopathologic and genomic characteristics, with class III alterations potentially associated with worse prognosis, according to research presented today at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

15 Sep 2026

Early consolidative SRT shows value in EGFR-mutant NSCLC with limited brain metastases

Early cranial stereotactic radiotherapy (SRT) administered with first-line osimertinib was associated with improved intracranial control and survival outcomes in patients with EGFR-mutant non-small cell lung cancer (NSCLC) and limited brain metastases, according to research presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

15 Sep 2026

Final results from PAPILLON trial confirm long-term survival in a subset of lung cancer

Final results from the landmark PAPILLON trial, which changed the standard of care for a difficult-to-treat rare form of lung cancer, confirm that amivantamab, when added to chemotherapy, provides durable clinical benefit and the longest median overall survival reported to date for people with the disease.

15 Sep 2026